CCO Infectious Disease Podcast

Key Decisions in HIV Care: Data on Long-Acting Injectable PrEP

Episode Summary

Listen as Jason Schafer, PharmD, MPH, shares the latest data to support long-acting PrEP, including efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.

Episode Notes

In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).

Listen as he gives his perspectives on the:

• PrEP pipeline and the importance of having options for patients with differing preferences
• FDA approval of long-acting cabotegravir for PrEP
• HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
• Safety data on long-acting cabotegravir for PrEP
• CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP

Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania 

Follow along with the slides at:
https://bit.ly/3tbvEPK

See the entire program at: 
https://bit.ly/3q2DlGd